alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 111.90 What requirements apply to treatments, in-process adjustments, and reprocessing when there is a deviation or unanticipated occurrence or when a specification established in accordance with § 111.70 is not met? ( a ) You must not reprocess a rejected dietary supplement or treat or provide an in-process adjustment to a component, packaging, or label to make it suitable for use in the manufacture of a dietary supplement unless: ( 1 ) Quality control personnel conduct a material review and make a disposition decision to approve the reprocessing, treatment, or in-process adjustment; and
( 2 ) The reprocessing, treatment, or in-process adjustment is permitted by § 111.77;
( b ) You must not reprocess any dietary supplement or treat or provide an in-process adjustment to a component to make it suitable for use in the manufacture of a dietary supplement, unless: ( 1 ) Quality control personnel conduct a material review and make a disposition decision that is based on a scientifically valid reason and approves the reprocessing, treatment, or in-process adjustment; and
( 2 ) The reprocessing, treatment or in-process adjustment is permitted by § 111.77;
( c ) Any batch of dietary supplement that is reprocessed, that contains components that you have treated, or to which you have made in-process adjustments to make them suitable for use in the manufacture of the dietary supplement must be approved by quality control personnel and comply with § 111.123(b) before releasing for distribution.
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.4580 Sonic surgical instrument and accessories/attachments. ( a ) *Identification.* A sonic surgical instrument is a hand-held device with various accessories or attachments, such as a cutting tip that vibrates at high frequencies, and is intended for medical purposes to cut bone or other materials, such as acrylic.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 888.9.
[52 FR 33702, Sept. 4, 1987, as amended at 84 FR 71818, Dec. 30, 2019]
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1890 Radiographic film illuminator. ( a ) *Identification.* A radiographic film illuminator is a device containing a visible light source covered with a translucent front that is intended to be used to view medical radiographs.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 892.9.
[55 FR 48444, Nov. 20, 1990, as amended at 65 FR 2323, Jan. 14, 2000]
| (logo)  WELLS FARGO | **Commercial  Mortgage Servicing**D1050-084,  8th Floor  401 South Tryon Street  Charlotte, NC 28202  1-800-326-1334 |
|---------------------|----------------------------------------------------------------------------------------------------------------------|

 

 

**ANNUAL STATEMENT OFCOMPLIANCE**

 

Referenceis hereby made to that certain Pooling and Servicing Agreement dated as of July1, 2015, by and among J.P. Morgan Chase Commercial Mortgage Securities Corp.,as Depositor, Wells Fargo Bank, National Association, as Master Servicer,Torchlight Loan Services, LLC, as Special Servicer, Wells Fargo Bank, NationalAssociation, as Certificate Administrator, Wilmington Trust, NationalAssociation, as Trustee, and Pentalpha Surveillance LLC, as Senior TrustAdvisor with respect to Commercial Mortgage Pass-Through Certificates Series2015-C30 (the "Agreement"). Capitalized terms used herein nototherwise defined shall have the meanings assigned in the Agreement.

 

Pursuantto Section 11.09 of this Agreement, I, Daniel Bober, Executive Vice Presidentof Commercial Mortgage Services do hereby certify that:

 

1. A review of the activities of theMaster Servicer during the period from January 1, 2017 through December 31,2017 (the “Reporting Period”), and of its performance per the Agreement duringsuch period has been made under my supervision, and

 

2. To the best of my knowledge, based onsuch review, the Master Servicer has fulfilled all of its obligations under theAgreement in all material respects throughout the Reporting Period.

 

 

INWITNESS WHEREOF, the undersigned has executed this Certificate as of the 28thday of February 2018.

 

/s/Daniel Bober

DanielBober

ExecutiveVice President

WellsFargo Bank

 

 

| Wells  Fargo Bank, N.A. | (logo) Together we’ll go far |
|-------------------------|------------------------------------|
### Don Pegues MAYOR citytke@gmail.com



### Mr. Todd Homan Director, Office ofAviation Analysis US Department ofTransportation 1200 New Jersey Avenue SE Washington, DC 20590 October 15, 2014

Dear 

### Mr. Homan: P.O. Box 52 

### Tenakee Springs, Alaska 99841 Phone 907-736-2207 Fax 907-736-2249

., ...!

•·· ''

.... I ;,, .:

The City ofTenakee Springs strongly objects to that portion ofyour order 2014-9-13 dated September 22, 2014, indicating the Department maybe considering termination ofsubsidized essential air service between Tenakee Springs and Juneau, Alaska. Inhis letter to you dated September 26, 2014, Angoon Mayor Matt Kookesh speaks for all ofus, and speaks well. Tenakee Springs and Angoon share the same flight pattern and ourrequirements are basically the same. Juneau has always beenthe hub ofair transport for our area and must remain as our EAS connection. Juneau was established as our hub city when Alaska Southern Airways established the first scheduled service inNorthern Southeast Alaska in early 1934. Later in 1934, PanAmerican Airways purchased Alaska Southern and announced expansion ofscheduled service, which included Tenakee Springs and Angoon. At a later date, after failing to receive the award ofa U.S. Mail contract for the area, Pan American elected to pull out ofthe Southeast Alaska floatplane operation and concentrate ontheir headquarters Alaska land base in Fairbanks. The floatplane operation in our area was then picked up by Juneau-based AlaskaAir Transport. This firm morphed into Alaska Coastal Airlines which over the years became a large regional carrier that eventually merged withpresent day Alaska Airlines. Following the merger, Alaska Airlines discontinued all water based operations and passed the mantle ofschedule floatplane service to emerging small earners.

# ··CITY OF TENAKEE SPRINGS

The first small carrierto provide Angoon/Tenakee scheduled service was Channel Flying Service, followed by Wings of**Alask~** then Alaska Seaplanes, our current carrier, all Juneau based. During the peakyears ofareatimber harvesting, 1960's and 1970's, limited scheduled 

### air service between Tenakee and Sitkawas provided by Channel Flying Service out ofJuneau, later followed byBell Air, based in Sitka. Scheduled service was discontinued when the timber industry shut down. Present day air service Sitka/Tenakee is provided on a charter basis by Harris Air Service ofSitka. Due to lack ofpassenger/cargo demand, these flights are few and far between. Harris Air does continue to provide scheduled service Sitka/ Angoon. And that is a briefhistory ofour air service. All ofTenakee's economic and social ties are with Juneau, not with Sitka. As written byAngoon Mayor Matt Kookesh, "the abandonment ofservice to Juneau 

### infavor ofless frequent and reduced capacity service to Sitka would be economically devastating to our communities."

Sincerely,

1947-1978 -Director

- PanAmerican World Airways, Alaska- Fairbanks AK 1979-2011- Tenakee Agent- Channel Flying, Wings ofAlaska, Alaska Seaplanes

Cc US Senator Mark Begich US Senator LisaMurkowski Representative Don Young
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3520 Rubeola (measles) virus serological reagents. ( a ) *Identification.* Rubeola (measles) virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to rubeola virus in serum. The identification aids in the diagnosis of measles and provides epidemiological information on the disease. Measles is an acute, highly infectious disease of the respiratory and reticuloendothelial tissues, particularly in children, characterized by a confluent and blotchy rash.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25047, June 12, 1989; 66 FR 38792, July 25, 2001]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3330 Preformed crown. ( a ) *Identification.* A preformed crown is a prefabricated device made of plastic or austenitic alloys or alloys containing 75 percent or greater gold and metals of the platinum group intended to be affixed temporarily to a tooth after removal of, or breakage of, the natural crown (that portion of the tooth that normally protrudes above the gums). It is intended for use as a functional restoration until a permanent crown is constructed. The device also may be intended for use as a functional restoration for a badly decayed deciduous (baby) tooth until the adult tooth erupts.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 59 FR 63008, Dec. 7, 1994; 66 FR 38798, July 25, 2001]
U.S. GOVERNMENT PUBLISHING OFFICE

WASHINGTON : 

1 

69–011 2017

115th Congress, 1st Session – – – – – – – – – – – – – House Document 115–30 

NOTIFICATION OF MISSILE STRIKES ON THE 

SHAYRAT MILITARY AIRFIELD IN SYRIA 

COMMUNICATION 

FROM

THE PRESIDENT OF THE UNITED STATES 

TRANSMITTING

A LETTER REGARDING ACTIONS TAKEN BY THE UNITED STATES 

MILITARY IN SYRIA ON APRIL 6, 2017, PURSUANT TO 50 U.S.C. 

1543(a); PUBLIC LAW 93–148, SEC. 4(a); (87 STAT. 555) 

APRIL 8, 2017.—Referred to the Committee on Foreign Affairs and ordered 

to be printed 


rfrederick on DSKBCBPHB2PROD with HEARINGE:\Seals\Congress.#13

rfrederick on DSKBCBPHB2PROD with HEARING
(1) 

THE WHITE HOUSE, 

Washington, April 8, 2017. 

Hon. PAUL D. RYAN, 

Speaker of the House of Representatives, 

Washington, DC. 

DEAR MR. SPEAKER: At approximately 8:40 p.m. Eastern Daylight Time on April 6, 2017, at my direction, United States military 

forces in the Mediterranean Sea, operating beyond the territorial 

sea of any state, struck the Shayrat military airfield in Syria. 

United States intelligence indicates that Syrian military forces operating from this airfield were responsible for the chemical weapons attack on Syrian civilians in southern Idlib Province, Syria, 

that occurred on April 4. I directed this action in order to degrade 

the Syrian military’s ability to conduct further chemical weapons 

attacks and to dissuade the Syrian regime from using or proliferating chemical weapons, thereby promoting the stability of the region and averting a worsening of the region’s current humanitarian 

catastrophe. 

I acted in the vital national security and foreign policy interests 

of the United States, pursuant to my constitutional authority to 

conduct foreign relations and as Commander in Chief and Chief 

Executive. The United States will take additional action, as necessary and appropriate, to further its important national interests. 

I am providing this report as part of my efforts to keep the Congress fully informed, consistent with the War Powers Resolution 

(Public Law 93–148). I appreciate the support of the Congress in 

this action. 

Sincerely, 

DONALD J. TRUMP. 

Æ 


rfrederick on DSKBCBPHB2PROD with HEARING
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.6 Degree of constraint. Certain joint prostheses provide more constraint of joint movement than others. FDA believes that the degree of constraint is an important factor affecting the safety and effectiveness of orthopedic prostheses. FDA is defining the following standard terms for categorizing the degree of constraint. ( a ) A “constrained” joint prosthesis is used for joint replacement and prevents dislocation of the prosthesis in more than one anatomic plane and consists of either a single, flexible, across-the-joint component or more than one component linked together or affined.
( b ) A “semi-constrained” joint prosthesis is used for partial or total joint replacement and limits translation and rotation of the prosthesis in one or more planes via the geometry of its articulating surfaces. It has no across-the-joint linkage.
( c ) A “non-constrained” joint prosthesis is used for partial or total joint replacement and restricts minimally prosthesis movement in one or more planes. Its components have no across-the-joint linkage.
**Exhibit 23.1**
**Consent of Independent Auditors**
We consent to the incorporation by reference in the Registration Statements(Form S-8 No. 333-13405 and No. 333-81023) pertaining to the Amended andRestated 1995 Equity Participation Plan of Ambassadors International, Inc. ofour report dated February 13, 2004, with respect to the consolidated financialstatements of Ambassadors International, Inc. included in the Annual Report(Form 10-K) for the year ended December 31, 2003.
Our audits also included the information as of and for the years ended December31, 2003 and 2002 included in the financial statement schedule of AmbassadorsInternational, Inc. listed in Item 15(a). This schedule is the responsibilityof the Company’s management. Our responsibility is to express an opinion basedon our audits. In our opinion, the financial statement schedule referred toabove, when considered in relation to the basic financial statements taken as awhole, presents fairly in all material respects the information set forththerein.       /s/ Ernst & Young LLP  
Irvine, California
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3320 *Histoplasma capsulatum* serological reagents. ( a ) *Identification. Histoplasma capsulatum* serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to *Histoplasma capsulatum* in serum. Additionally, some of these reagents consist of *Histoplasma capsulatum* antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify *Histoplasma capsulatum* from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of histoplasmosis caused by this fungus belonging to the genus *Histoplasma* and provides epidemiological information on the diseases caused by this fungus. Histoplasmosis usually is a mild and often asymptomatic respiratory infection, but in a small number of infected individuals the lesions may spread to practically all tissues and organs.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 63 FR 59227, Nov. 3, 1998]
# C_2014329EN.01001401.xml

| 22.9.2014 | EN | Official Journal of the European Union | C 329/14 |
| --- | --- | --- | --- |

22.9.2014

EN

Official Journal of the European Union

C 329/14

---

Order of the President of the General Court of 10 June 2014 — Stahlwerk Bous v Commission

(Case T-172/14 R)

((Interim measures - State aid - National promotion of electricity production from a renewable source - Commission decision to open formal investigation procedure in respect of State aid - Application for suspension of operation of a measure - Urgency - Fumus boni juris))

2014/C 329/17

Language of the case: German

Parties

Parties

Applicant: Stahlwerk Bous GmbH (Bous, Germany) (represented by: H. Höfler, C. Kahle and V. Winkler, lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian Rusche and R. Sauer, Agents)

Defendant:

Re:

Re:

Application for suspension of the legal effects of the decision by which the Commission opened a formal investigation procedure in respect of State aid concerning the German law on renewable energy.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The judgment of 7 April 2014 in Case T-172/14 R Stahlwerk Bous v Commission is set aside. |
| --- | --- |

2.

The judgment of 7 April 2014 in Case T-172/14 R Stahlwerk Bous v Commission is set aside.

| 3. | Costs are reserved. |
| --- | --- |

3.

Costs are reserved.

---
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.4300 Manual cranial drills, burrs, trephines, and their accessories ( a ) *Identification.* Manual cranial drills, burrs, trephines, and their accessories are bone cutting and drilling instruments that are used without a power source on a patient's skull.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3535 Knee joint femorotibial (uni-compartmental) metal/polymer porous-coated uncemented prosthesis. ( a ) *Identification.* A knee joint femorotibial (uni-compartmental) metal/polymer porous-coated uncemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surface. It has no linkage across-the-joint. This generic type of device is designed to achieve biological fixation to bone without the use of bone cement. This identification includes fixed-bearing knee prostheses where the ultra-high molecular weight polyethylene tibial bearing is rigidly secured to the metal tibial baseplate.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance: “Class II Special Controls Guidance Document: Knee Joint Patellofemorotibial and Femorotibial Metal/Polymer Porous-Coated Uncemented Prostheses; Guidance for Industry and FDA.” See § 888.1 for the availability of this guidance.
[68 FR 14137, Mar. 24, 2003]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Consumer Product Safety Commission

# TIME AND DATE:

 Wednesday, March 10, 2010, 9 a.m.-12 Noon.

# PLACE:

 Hearing Room 420, Bethesda Towers, 4330 East West Highway, Bethesda, Maryland.

# STATUS:

 Commission Meeting—Open to the Public.

# MATTERS TO BE CONSIDERED:

1. Pending Decisional Matter: Civil Penalty Factors—Final Rule.

2. Toddler Beds—Notice of Public Rulemaking (NPR).

                        A live webcast of the Meeting can be viewed at                         *http://www.cpsc.gov/​webcast/​index.html.*

For a recorded message containing the latest agenda information, call (301) 504-7948.

# CONTACT PERSON FOR MORE INFORMATION:

 Todd A. Stevenson, Office of the Secretary, U.S. Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814 (301) 504-7923.

Dated: March 1, 2010.

Todd A. Stevenson,

Secretary.

[FR Doc. 2010-4696 Filed 3-2-10; 4:15 pm]

BILLING CODE 6355-01-P
#### Crist *v.*The Wayne International Building and Loan Association.

[No. 18,793.

Filed June 5, 1900.

Rehearing denied July 10, 1900.]

*Appeal.*— Joint *Assignment of Errors.*— An assignment of errors joined in by one who did not appear in the court below, and who took no exception to any action or ruling of the court, is insufficient.

Prom the Huntington Circuit Court.

*Affirmed.*

*T. G. Smith,*for appellant.

*J. M. Hatfield*and *Griffith & Flinn,*for appellee.

Monks, J.

— Appellee brought this action to foreclose a mortgage on real estate, executed by appellants, Jennie Crist and Lyman C. Crist, her husband, to secure an indebtedness evidenced by a bond executed by said Jennie Crist. Afterwards the appellant, Minnie Pashong, upon her application showing that she claimed an interest in the real estate described in said mortgage superior to and free from the lien of said mortgage, was by the court made a defendant to this action. Appellant Jennie Crist made default. After issues were joined the cause was tried by the court, special finding of facts made, and conclusions of law stated thereon in favor of appellee, and, over a motion for a new trial by appellants Lyman C. Crist and Minnie Pashong, a decree of foreclosure was rendered ordering the sale of said real estate to pay the indebtedness secured by said *261mortgage. Appellants, Lyman C. Crist, Jennie C. Crist, ■ and Minnie Pashong join in the assignment of errors.

The rulings of the court assigned as errors affect only the appellants Lyman C. Crist and Minnie Pashong, either jointly or severally, and no ruling or action of the court affecting all the appellants jointly is assigned as error. It is evident that said assignment of errors was not good as to appellant Jennie Crist, who did not appear in the court below, and who took no exception to any action or ruling of the court.

It is settled law in this State that if several appellants join in an assignment of errors it must be good as to all the persons joining therein, or it will be insufficient as to each of them. Ewbank’s Manual, §138; *Sweeney Co.*v. *Fry,*151 Ind. 1Y8, 181, 182, and cases cited; Elliott’s App. Proc. §839.

Judgment affirmed.
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5030 Methyl methacrylate for aneurysmorrhaphy. ( a ) *Identification.* Methyl methacrylate for aneurysmorrhaphy (repair of aneurysms, which are balloonlike sacs formed on blood vessels) is a self-curing acrylic used to encase and reinforce intracranial aneurysms that are not amenable to conservative management, removal, or obliteration by aneurysm clip.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1940 Tonometer sterilizer. ( a ) *Identification.* A tonometer sterilizer is an AC-powered device intended to heat sterilize a tonometer (a device used to measure intraocular pressure).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 886.9.
[55 FR 48443, Nov. 20, 1990, as amended at 65 FR 2321, Jan. 14, 2000]
#### The People of the State of Illinois, Plaintiff-Appellee, v. John Allen Curry, Defendant-Appellant.

Gen. No. 68-80.

Third District.

March 27, 1969.

John Allen Curry, pro se, of Joliet, and Vilas Rice, of Carthage, for appellant; Max Stewart, State’s Attorney of Hancock County, of Carthage, for appellee.

Opinion by

JUSTICE RYAN.

Not to be published in full.